Versartis to Present at the Cowen and Company 36th Annual Health Care Conference

MENLO PARK, Calif., March 01, 2016 -- Versartis, Inc. (NASDAQ:VSAR), an endocrine-focused biopharmaceutical company that is developing somavaratan (VRS-317), a novel, long-acting form of recombinant human growth hormone (rhGH) for growth hormone deficiency (GHD), today announced that Mr. Jay Shepard, President and Chief Executive Officer, is scheduled to present at the Cowen and Company 36th Annual Health Care Conference on March 8, 2016, at the Boston Marriott Copley Place in Boston, Massachusetts.

Event: Cowen and Company 36th Annual Health Care Conference
Date: Tuesday, March 8, 2016
Time: 8:40 a.m. ET
Location: Boston Marriott Copley Place - Boston, MA

An audio webcast of the Company's presentation will be available on the investor relations section of the Versartis website at www.versartis.com. A replay of the presentation will be available for 90 days.

About Versartis, Inc.
Versartis, Inc. is an endocrine-focused biopharmaceutical company initially developing somavaratan (VRS-317), a novel, long-acting form of recombinant human growth hormone in late-stage clinical trials for the treatment of growth hormone deficiency (GHD) in children and adults. Somavaratan is intended to reduce the burden of daily injection therapy by requiring significantly fewer injections, potentially improving compliance and, therefore, treatment outcomes. Versartis' clinical trials can be found at www.versartistrials.com. For more information on Versartis, visit www.versartis.com.

Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding our intentions or current expectations concerning, among other things, plans and timing of our clinical trials and the potential for eventual regulatory approval of somavaratan. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated. We discuss many of these risks in greater detail under the heading "Risk Factors" contained in our Annual Report on Form 10-K for the year ended December 31, 2014, and in our Quarterly Report on Form 10-Q for the three months ended September 30, 2015, which are on file with the Securities and Exchange Commission (SEC). Forward-looking statements are not guarantees of future performance, and our actual results may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that we make in this press release speak only as of the date of this press release and we assume no obligation to update our forward-looking statements after the date of this press release.

Contacts:

Corporate & Investors:
Joshua Brumm
Chief Financial Officer
(650) 963-8582
[email protected]

Corporate Communications: 
Christine Labaree
Evergreen Communications
(650) 600-1697
[email protected]

Investors:
Nick Laudico/David Burke
The Ruth Group
(646) 536-7030/7009
[email protected]
[email protected]